# Fate Therapeutics (FATE) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/FATE
## Company Profile
- Ticker: FATE
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 2.6 USD
- Market cap: 299557108.02 USD
- Last updated: 2026-08-05
## Business Overview
### iPSC-Derived Cell Therapy Platform
Fate Therapeutics develops off-the-shelf cellular immunotherapies manufactured from induced pluripotent stem cells.
### FT819
FT819 is an iPSC-derived CD19 CAR T-cell therapy for autoimmune disease. The platform is intended to provide standardized manufacturing and repeatable dosing without patient-specific cell collection.
### Lupus Development
Clinical work includes systemic lupus erythematosus and lupus nephritis, using reduced conditioning to improve treatment accessibility.
### Broader Pipeline
FT839 is an earlier program designed for broad targeting of hematologic malignancies and autoimmune disease without conventional conditioning chemotherapy.
## Why The Stock Is Moving

As of Aug 5, 2026, FATE closed up 1.17% at $2.60. No new same-company headline was identified in the current news window.

## Future Catalysts

- The potentially registrational Phase 2 RECLAIM-LN study of FT819 in refractory lupus nephritis is scheduled to begin in the second half of 2026.

## Drug Assets

- FT819

## Recent News
- 2026-08-03 20:05 EST — [Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-ru-852a06cf) — Source: Fate Therapeutics
- 2026-07-09 12:30 EST — [Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate](https://biopharmsignal.com/news/FATE/fate-therapeutics-receives-fda-clearance-of-investigational-new-drug-application-5f43a8db) — Source: Fate Therapeutics
- 2026-07-06 12:30 EST — [Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-to-present-preliminary-clinical-data-of-ft819-off-the-shelf-ca-2ca1e01e) — Source: Fate Therapeutics
- 2026-07-01 20:05 EST — [Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences](https://biopharmsignal.com/news/FATE/fate-therapeutics-to-participate-in-upcoming-third-quarter-2026-conferences-457e2808) — Source: Fate Therapeutics
- 2026-06-15 12:30 EST — [Fate Therapeutics Appoints Laura Hamill to Board of Directors](https://biopharmsignal.com/news/FATE/fate-therapeutics-appoints-laura-hamill-to-board-of-directors-d47c62a6) — Source: Fate Therapeutics